NEW YORK (GenomeWeb) – Qiagen said today that it has initiated a clinical development program with Novartis for a molecular companion diagnostic to guide the use of a Novartis investigational PI3K inhibitor in certain breast cancer patients.

Specifically, the proposed CDx would guide use of Novartis' BYL719 (alpelisib) in combination with fulvestrant for men and postmenopausal women with PIK3CA-mutated, hormone receptor-positive, EGFR receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.